Nanoparticle-based compositions
Provided herein are new compositions including an inactivated pathogen and one or more adjuvant-loaded polymeric nanoparticles, wherein the adjuvant-loaded nanoparticles are bound to the inactivated pathogen. These compositions are useful for preventing and/or treating diseases caused by the specific pathogens, especially when administered to a subject's mucosal membranes.
1. A method of stimulating a resident mucosal memory T cell immune response against Chlamydia trachomatis in a subject in need thereof, the method comprising administering to the subject through a mucosal route an effective amount of a composition comprising a negatively charged inactivated Chlamydia trachomatis , and one or more adjuvant-loaded polymeric nanoparticles having a positive charge, wherein the one or more adjuvant-loaded polymeric nanoparticles are each attached to the inactivated Chlamydia trachomatis through electrostatic attraction, and the one or more adjuvant-loaded nanoparticles comprise poly(lactic-co-glycolic acid)-block-poly(L-histidine)-block-poly(ethylene glycol) (PLGA-PLH-PEG) triblock copolymers, thereby stimulating a resident mucosal memory T cell immune response against Chlamydia trachomatis in the subject.
2. The method of claim 1 , wherein the one or more adjuvant-loaded polymeric nanoparticles comprise an adjuvant that targets an endosomal membrane.
3. The method of claim 1 , wherein the one or more adjuvant-loaded polymeric nanoparticles comprise a Toll-like receptor agonist.
4. The method of claim 1 , wherein the one or more adjuvant-loaded polymeric nanoparticles comprise biodegradable polymers.
5. The method of claim 1 , wherein the one or more adjuvant-loaded polymeric nanoparticles comprise R848-polylactic acid.
6. The method of claim 1 , wherein the composition is administered to the subject by an intranasal route.
7. The method of claim 1 , wherein the composition is administered to the subject by an intrauterine route.